Objective: To establish a liquid chromatography tandem mass spectrometry method for the determination of ubenimex in human plasma.
Methods: The essay was conducted with an API 3000 HPLC-MS/MS system consisted of a Ultimate C18 column (50 mm x 4.6 mm, 5 microm). The mobile phase consisted of methanol-water-formic acid (70 : 30 : 0.05, V/V/V) at a flow rate of 0.2 mL/min. Granisetron was used as the internal standard. The sample was extracted by solid phase extraction column and was operated under the multiple reaction monitoring mode using the electrospray ionization technique in positive mode.
Results: The linear range of ubenimex was 0.4-4000 ng/mL. The limit of quantity was set at 0.4 ng/mL. The within-day and between-day variations were less than 6%.
Conclusion: This method for the quantitative determination of ubenimex was proved to be accurate, sensitive, selective and convenient and can be applied in the determination of ubenimex in human plasma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Why Bestatin Prefers Human Carnosinase 2 (CN2) to Human Carnosinase 1 (CN1).
J Phys Chem B
December 2024
Department of Chemistry, Faculty of Science, Kasetsart University, Chatuchak, Bangkok 10900, Thailand.
Human carnosinases (CNs) are Xaa-His metal-ion-activated aminopeptidases that break down bioactive carnosine and other histidine-containing dipeptides. Carnosine is a bioactive peptide found in meat and prevalently used as a supplement and in functional food formulation. Nonetheless, carnosine is digested by CNs rapidly after ingestion.
View Article and Find Full Text PDFThe triple combination DBDx alleviates cytokine storm and related lung injury.
Int Immunopharmacol
December 2024
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Cytokine storm is a life-threatening disorder, and therapeutic treatments are urgently needed. Here, we investigated the anti-cytokine storm efficacy of DBDx, a triple drug combination composed of dipyridamole, ubenimex and dexamethasone. Evaluated by lipopolysaccharide (LPS)-induced cytokine storm murine model, DBDx significantly improved survival rate and prolonged survival time of the model mice.
View Article and Find Full Text PDFCurcumin suppresses colorectal tumorigenesis through restoring the gut microbiota and metabolites.
BMC Cancer
September 2024
Jiangxi Provincial Key Laboratory of Prevention and Treatment of Infectious Diseases, Jiangxi Medical Center for Critical Public Health Events, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330052, Jiangxi, P.R. China.
Article Synopsis
- - Curcumin shows potential for preventing and treating colorectal cancer (CRC) by influencing gut microbiota and its metabolites, although its exact mechanisms are not fully understood.
- - In a study with C57BL/6JGpt mice, curcumin treatment improved colon structure, reduced tumor formation, and positively altered gut bacteria diversity compared to CRC mice that did not receive curcumin.
- - The research found that curcumin decreased harmful bacteria and increased beneficial ones, along with identifying 13 metabolites that were altered in the CRC model group, suggesting a significant impact on gut health related to CRC.
A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q).
Clin Lung Cancer
January 2024
Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
Article Synopsis
- The KEYNOTE-407 trial established pembrolizumab plus platinum-based chemotherapy as the standard treatment for advanced squamous non-small-cell lung cancer (NSCLC), and this study will evaluate the drug ubenimex when combined with this regimen.
- Conducted as a phase II clinical trial, patients will receive ubenimex along with pembrolizumab, nab-paclitaxel, and carboplatin, with a focus on establishing safety and efficacy through systematic dose escalation.
- This trial represents the first investigation of ubenimex in this combination treatment, and its findings could inform future therapeutic approaches for patients with advanced squamous NSCLC.
Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer.
Molecules
August 2023
Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China.
The CD13 inhibitor ubenimex is used as an adjuvant drug with chemotherapy for the treatment of cancer due to its function as an immunoenhancer, but it has limitations in its cytotoxic efficacy. The proteasome inhibitor ixazomib is a landmark drug in the treatment of multiple myeloma with a high anti-cancer activity. Herein, we conjugated the pharmacophore of ubenimex and the boric acid of ixazomib to obtain a dual CD13 and proteasome inhibitor ().
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!